Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

Abstract The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and li...

Full description

Saved in:
Bibliographic Details
Main Authors: Bertin C. Bisimwa, Esto Bahizire, Maja Kiselinova, Valéry Byela, Jean Claude S. Ngabonziza, François Hakizayezu, Docteur Runyambo, Conor J. Meehan, Wim Mulders, Isabel Cuella-Martin, Leen Rigouts, Freddy Birembano, Steven Callens, Bouke C. de Jong, Michel Kaswa
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Infectious Diseases
Subjects:
Drug resistance
Linezolid and Delamanid
Novel mutations
Online Access:https://doi.org/10.1186/s12879-025-11348-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.
ISSN:1471-2334

Similar Items